V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 190007264 | 190008054 | 0 | 87 | null | 2021-03-05 | 2021-08-05 | EW EuroEwing 2012 Arm B VDC/IE | 02 | N | AZACITIDINE | 101834705 |
| 190009411 | 190008055 | 0 | 57.1 | Neo-adjuvant (N) | 2019-08-03 | 2020-01-22 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 02 | null | OST MIFAMURTIDE | 101440369 |
| 190010127 | 190008056 | 0 | 56.9 | Palliative (P) | 2021-07-04 | 2021-07-11 | OST Mifamurtide | null | null | NB HRNBL-1 BUMEL MAT | 100767437 |
| 190005101 | 190008071 | null | null | null | null | 2018-08-27 | null | null | null | MIFAMURTIDE | 101176674 |
| 190005676 | 190008078 | null | null | null | null | 2022-02-10 | null | null | null | MIFAMURTIDE | 101632912 |
| 190006524 | 190008087 | null | null | Curative (C) | null | 2018-07-24 | null | null | null | MIFAMURTIDE | 100275336 |
| 190006783 | 190008089 | null | null | null | null | 2017-12-19 | null | null | null | MIFAMURTIDE | 101329351 |
| 190008417 | 190008105 | null | null | null | null | 2020-04-21 | null | null | null | MIFAMURTIDE | 100275307 |
| 190008817 | 190008112 | null | null | null | null | 2020-02-09 | null | null | null | MIFAMURTIDE | 101375934 |
| 190008819 | 190008113 | 1.64 | null | null | null | 2022-04-08 | STS Rhabdo RMS 2005 2nd Topo Cyclo | 02 | null | CARBOPLATIN + ETOPOSIDE | 100543326 |
| 190008969 | 190008114 | null | 65.7 | Curative (C) | 2021-09-26 | 2021-09-26 | Irinotecan + Temozolomide | N | N | CAPECITABINE | 101317787 |
| 190009035 | 190008116 | 1.59 | 73 | Palliative (P) | 2016-01-15 | 2016-07-04 | EW Rel rEECur Irinotecan/Temozolomide | null | null | BEVACIZUMAB | 100827071 |
| 190009051 | 190008117 | 1.69 | 45 | 03 | 2021-01-26 | 2021-02-03 | ETOPOSIDE | 02 | N | CAPECITABINE + CARBOPLATIN | 100985989 |
| 190009152 | 190008118 | 1.7 | null | Neo-adjuvant (N) | 2021-10-18 | 2022-02-15 | OST Euramos 1 Closed Trial - AP | 01 | N | CARBOPLATIN + FLUOROURACIL | 100349515 |
| 190009326 | 190008120 | null | 67.2 | Adjuvant (A) | 2017-08-29 | 2017-08-29 | Irinotecan + Modified De Gramont | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100858772 |
| 190009396 | 190008121 | 1.58 | 69.8 | null | 2021-10-05 | 2021-10-16 | null | 02 | N | FLUOROURACIL | 101470043 |
| 190009397 | 190008122 | 0 | 42.5 | null | 2017-02-13 | 2017-02-21 | Cisplatin + Radiotherapy | null | null | CARBOPLATIN + PACLITAXEL + RT | 100097636 |
| 190009505 | 190008123 | 1.56 | 57.3 | Curative (C) | null | 2019-07-12 | CASPS TRIAL | 02 | null | CAPECITABINE + IRINOTECAN | 100154257 |
| 190009744 | 190008125 | 1.59 | 59.8 | Palliative (P) | 2016-07-27 | 2016-08-17 | Doxorubicin + Methotrexate | 02 | null | CAV | 100054242 |
| 190009768 | 190008126 | 1.64 | 111 | Curative (C) | null | 2022-05-15 | PAM x 2 post-surgery (cycles 3&4) | 02 | N | CISPLATIN + DOXORUBICIN + METHOTREXATE | 101135474 |
| 190009780 | 190008127 | null | 78.6 | Palliative (P) | 2020-09-29 | 2021-03-25 | BEP 3 day | 02 | null | BEVACIZUMAB | 100020687 |
| 190009824 | 190008129 | 0 | 47.8 | null | 2020-10-16 | 2020-10-25 | DOXORUBICIN | 01 | N | DOXORUBICIN | 101041721 |
| 190009878 | 190008130 | 0 | 60.9 | Curative (C) | 2020-06-16 | 2021-02-16 | CARBOPLATIN + FLUOROURACIL | 02 | null | TRIAL | 100482626 |
| 190009897 | 190008131 | 0 | 48.4 | Curative (C) | 2020-01-26 | 2020-02-04 | Methotrexate High Dose (3g/m2) | 02 | null | METHOTREXATE | 101513878 |
| 190009910 | 190008132 | 1.72 | 55 | Palliative (P) | null | 2016-06-16 | GEMCITABINE | 02 | Y | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 101791109 |
| 190009950 | 190008133 | 1.63 | 61 | Curative (C) | null | 2020-06-25 | Trastuzumab Subcutaneous | 02 | null | CISPLATIN + CYTARABINE | 100607227 |
| 190010002 | 190008134 | 1.79 | 65.6 | null | 2020-02-20 | 2020-04-15 | CISPLATIN + GEMCITABINE | 02 | N | EW REL REECUR IFOSFAMIDE | 100064157 |
| 190010044 | 190008135 | 0 | 31.2 | Curative (C) | 2022-04-09 | 2022-04-17 | Cisplatin + Doxorubicin | 02 | null | TRIAL | 101484428 |
| 190010091 | 190008136 | 1.63 | 68.8 | Neo-adjuvant (N) | 2020-12-24 | 2021-01-24 | TOPOTECAN | 02 | N | NOT MATCHED | 101727589 |
| 190010093 | 190008137 | 1.66 | 84 | null | 2022-04-24 | 2022-05-29 | EURAMOS TRIAL | null | null | TRASTUZUMAB | 101125124 |
| 190010117 | 190008138 | 0 | 63.4 | null | null | 2021-09-25 | DOXORUBICIN | 02 | null | DOXORUBICIN | 100494715 |
| 190010126 | 190008139 | 1.68 | 67.4 | null | 2020-10-22 | 2020-11-24 | PAM | 02 | N | CISPLATIN + DOXORUBICIN + METHOTREXATE | 100810176 |
| 190010150 | 190008140 | 0 | 36.1 | null | 2019-11-09 | 2019-11-19 | null | 02 | N | MAP | 100080628 |
| 190010254 | 190008141 | 0 | 48 | null | 2019-04-29 | 2019-04-29 | EW EuroEwing 2012 Arm B IE | 02 | N | EW EUROEWING 2012 ARM B IE | 101655316 |
| 190010259 | 190008142 | 1.77 | 59.4 | Palliative (P) | 2020-05-15 | 2020-05-15 | DOXORUBICIN | 02 | N | DOXORUBICIN | 101864734 |
| 190010347 | 190008143 | 0 | 0 | 03 | 2017-03-02 | 2017-06-23 | ETOPOSIDE + IFOSFAMIDE | 02 | null | ETOPOSIDE + IFOSFAMIDE | 100457965 |
| 190010358 | 190008144 | 0 | 0 | Curative (C) | 2020-08-14 | 2020-09-08 | Docetaxel+Gemcitabine (no prior RT) | 02 | N | DOCETAXEL + GEMCITABINE | 100958431 |
| 190010360 | 190008145 | 0 | 51.9 | Palliative (P) | 2020-10-08 | 2020-10-28 | ECX | null | null | CYTARABINE | 100086863 |
| 190010459 | 190008146 | 1.8 | 82.4 | Neo-adjuvant (N) | 2020-06-06 | 2020-06-06 | Etoposide + Ifosfamide (5 days) | 02 | null | ETOPOSIDE + IFOSFAMIDE | 101317669 |
| 190010473 | 190008147 | 1.58 | 64.1 | Palliative (P) | 2021-06-09 | 2021-07-18 | Etoposide + Ifosfamide (3 days) | 02 | N | ETOPOSIDE + IFOSFAMIDE | 100010762 |
| 190010523 | 190008148 | 1.5 | 23.6 | Curative (C) | 2016-10-01 | 2016-10-22 | Cyclophosphamide High Dose | 02 | N | MELPHALAN + TREOSULPHAN | 100632183 |
| 190010554 | 190008149 | 0 | 31.2 | null | 2019-10-15 | 2020-03-22 | OST Euramos 1 Closed Trial - M | null | null | OST M | 101448429 |
| 190010596 | 190008150 | 1.67 | 88.25 | null | 2020-09-28 | 2020-09-28 | OST Euramos 1 Closed Trial - M | 02 | N | OST M | 100167309 |
| 190010621 | 190008151 | 1.88 | 100.5 | Adjuvant (A) | 2016-11-12 | 2016-11-12 | EW EuroEwing 2012 Arm B VC | 02 | N | EW EUROEWING 2012 ARM B VC | 100869513 |
| 190010650 | 190008152 | 0 | null | Curative (C) | 2018-10-31 | 2018-12-16 | ETOPOSIDE + IFOSFAMIDE | null | null | ETOPOSIDE + IFOSFAMIDE | 100561190 |
| 190010685 | 190008153 | 0 | 49.5 | Neo-adjuvant (N) | 2022-02-04 | 2022-03-05 | DOXORUBICIN | Y | N | DOXORUBICIN | 101159852 |
| 190010719 | 190008154 | 1.75 | 55 | Palliative (P) | 2018-12-21 | 2019-03-14 | Docetaxel+Gemcitabine (no prior RT) | 02 | null | DOCETAXEL + GEMCITABINE | 100144097 |
| 190010755 | 190008155 | 0 | 41.9 | null | 2019-01-26 | 2019-04-26 | Gemcitabine + Capecitabine | 02 | N | VIDE | 101847115 |
| 190010837 | 190008156 | 1.66 | 57 | Disease modification (D) | 2019-04-22 | 2019-11-09 | OST Euramos 1 Closed Trial - M | 01 | N | OST M | 101586453 |
| 190010853 | 190008157 | 1.7 | 105.4 | Palliative (P) | 2020-08-14 | 2020-08-21 | Liposomal Doxorubicin (Caelyx) | null | null | EW REL REECUR GEMCITABINE/DOCETAXEL | 100377460 |